UAE Claims 86% effectiveness of Sinopharm COVID Vaccine, Experts Question Failure to Account for Clinical Test Data
The UAE health authorities announced on Wednesday (Dec 9) that the Chinese Sinopharm COVID-19 vaccine has been tested and confirmed to be 86% effective, making it the first country in the world to certify the effectiveness of a Chinese-made vaccine. However, some academics, holding a wait-and-see attitude, believe that the UAE authorities have not provided key and detailed information, including data from the Phase 3 clinical trials.
The UAE is one of the ten countries where two of Sinopharm’ vaccines are undergoing clinical trials. UAE indicated that it had approved an interim analysis of the vaccine’s Phase 3 clinical trial data, which showed 100% effectiveness in preventing mild symptoms from turning into moderate to severe conditions. They also claimed an overall effective protection rate of 86%, adding that the vaccine poses no serious safety concerns.
The Sinopharm Group did not confirm the news or comment to the media for several hours after UAE’s announcement. The New York Times even reported that it was disconnected when it tried to reach the group on the phone. It was only at dusk on Thursday (Dec 10) that Sinopharm uploaded its vaccine registration statement for the UAE. Still, it did not provide further data on the Phase 3 tests, such as the number of people infected with the vaccine and the volunteers’ age. The group also did not make any “welcome” remarks.
#UAE #China #Sinopharm #COVID19 #Vaccines #Trials #TestData #NewYorkTimes
Source: Stand News #Dec11
https://bit.ly/3i0j9zj
The UAE health authorities announced on Wednesday (Dec 9) that the Chinese Sinopharm COVID-19 vaccine has been tested and confirmed to be 86% effective, making it the first country in the world to certify the effectiveness of a Chinese-made vaccine. However, some academics, holding a wait-and-see attitude, believe that the UAE authorities have not provided key and detailed information, including data from the Phase 3 clinical trials.
The UAE is one of the ten countries where two of Sinopharm’ vaccines are undergoing clinical trials. UAE indicated that it had approved an interim analysis of the vaccine’s Phase 3 clinical trial data, which showed 100% effectiveness in preventing mild symptoms from turning into moderate to severe conditions. They also claimed an overall effective protection rate of 86%, adding that the vaccine poses no serious safety concerns.
The Sinopharm Group did not confirm the news or comment to the media for several hours after UAE’s announcement. The New York Times even reported that it was disconnected when it tried to reach the group on the phone. It was only at dusk on Thursday (Dec 10) that Sinopharm uploaded its vaccine registration statement for the UAE. Still, it did not provide further data on the Phase 3 tests, such as the number of people infected with the vaccine and the volunteers’ age. The group also did not make any “welcome” remarks.
#UAE #China #Sinopharm #COVID19 #Vaccines #Trials #TestData #NewYorkTimes
Source: Stand News #Dec11
https://bit.ly/3i0j9zj
立場新聞 Stand News
阿聯酋宣稱中國國藥武肺疫苗 86% 有效 專家質疑未交代臨床測試數據 | 立場報道 | 立場新聞
阿聯酋衛生部門周三（9 日）宣布，指經測試證實中國國藥控股研發的武漢肺炎（COVID-19）疫苗有效率達 86...